Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Finished Drug Prices
NA
1. (2r,6s,12z,13as,14ar,16as)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazin-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16atetradecahydrocyclopropa(e)pyrrolo(1,2-a)(1,4)diazacyclopentadecine-14a(5h)-carboxamide
2. Abt 450
3. Abt-450
4. Abt450
5. Paritaprevir Dihydrate
6. Paritaprevir Hydrate
7. Veruprevir
8. Veruprevir Anhydrous
1. Veruprevir
2. Abt-450
3. Veruprevir Anhydrous
4. 1216941-48-8
5. Abt450
6. 1221573-85-8
7. Ou2ym37k86
8. (2r,6s,12z,13as,14ar,16as)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazin-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16atetradecahydrocyclopropa(e)pyrrolo(1,2-a)(1,4)diazacyclopentadecine-14a(5h)-carboxamide
9. Paritaprevir(abt-450)
10. (2r,6s,13as,14ar,16as,z)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide
11. Abt 450
12. Veruprevir [inn]
13. Paritaprevir [usan]
14. Paritaprevir [usan:inn]
15. Unii-ou2ym37k86
16. Paritaprevir [mi]
17. Paritaprevir [inn]
18. Paritaprevir [vandf]
19. Veruprevir (deprecated Inn)
20. Paritaprevir [who-dd]
21. Schembl3069964
22. Chembl3391662
23. Gtpl11273
24. Amy6938
25. Dtxsid601027922
26. Paritaprevir [orange Book]
27. Paritaprevir(veruprevir Abt-450)
28. (2r,6s,12z,13ar,14ar,16as)-n-(cyclopropanesulfonyl)-6-[(5-methylpyrazine-2-carbonyl)amino]-5,16-dioxo-2-[(phenanthridin-6-yl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5h)-carboxamide
29. Ex-a2278
30. S5404
31. Viekirax Component Paritaprevir
32. Akos025396424
33. Zinc197964623
34. Ccg-270449
35. Cs-5051
36. Db09297
37. Ncgc00509859-02
38. Paritaprevir Component Of Viekirax
39. Ac-33061
40. As-75348
41. Hy-12594
42. A857160
43. (1s,4r,6s,7z,14s,18r)-n-(cyclopropanesulfonyl)-14-(5-methylpyrazine-2-amido)-2,15-dioxo-18-(phenanthridin-6-yloxy)-3,16-diazatricyclo[14.3.0.0?,?]nonadec-7-ene-4-carboxamide
44. (1s,4r,6s,7z,14s,18r)-n-cyclopropylsulfonyl-14-[(5-methylpyrazine-2-carbonyl)amino]-2,15-dioxo-18-phenanthridin-6-yloxy-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxamide
45. (2r,6s,12z,13as,14ar,16as)-n-(cyclopropylsulfonyl)-6-{[(5-methyl-2-pyrazinyl)carbonyl]amino}-5,16-dioxo-2-(6-phenanthridinyloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5h)-carboxamide
46. (2r,6s,13as,14ar,16as,z)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5h)-carboxamide
47. Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5h)-carboxamide, N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[(5-methyl-2-pyrazinyl)carbonyl]amino]-5,16-dioxo-2-(6-phenanthridinyloxy)-, (2r,6s,12z,13as,14ar,16as)-
Molecular Weight | 765.9 g/mol |
---|---|
Molecular Formula | C40H43N7O7S |
XLogP3 | 4.7 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 7 |
Exact Mass | 765.29446791 g/mol |
Monoisotopic Mass | 765.29446791 g/mol |
Topological Polar Surface Area | 198 Ų |
Heavy Atom Count | 55 |
Formal Charge | 0 |
Complexity | 1600 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 5 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
When used within the fixed-dose combination product with [DB09296], [DB09183], and [DB00503] as the FDA-approved product Viekira Pak, paritaprevir is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with [DB00811] for the treatment of HCV genotype 1a without cirrhosis or with compensated cirrhosis. When used within the fixed-dose combination product with [DB09296] and [DB00503] as the FDA- and Health Canada-approved product Technivie, paritaprevir is indicated in combination with [DB00811] for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis. When used within the fixed-dose combination product with [DB09296], [DB09183], and [DB00503] as the Health Canada-approved, commercially available product Holkira Pak, paritaprevir is indicated for the treatment of HCV genotype 1b with or without cirrhosis, and when combined with [DB00811] for the treatment of HCV genotype 1a with or without cirrhosis.
FDA Label
At concentrations approximately 6 and 1.8 times the therapeutic concentrations of paritaprevir and ombitasvir, the combination did not prolong QTc to any clinically relevant extent.
Absorption
Tmax of approximately 4 to 5 hours with a maximum concentration (Cmax) of 194 ng/mL.
Route of Elimination
Following a single dose administration of 14C-paritaprevir co-dosed with 100 mg of ritonavir, approximately 88% of the radioactivity was recovered in feces with limited radioactivity (8.8%) in urine; unchanged paritaprevir accounted for 1.1% of the radioactivity in the feces and 0.05% in the urine.
Volume of Distribution
Volume of distribution at steady state is approximately 103 L.
Paritaprevir is predominantly metabolized by CYP3A4 and to a lesser extent by CYP3A5.
5.5 hr
Paritaprevir is a potent inhibitor of the NS3/4A serine protease of Hepatitis C Virus (HCV). Following viral replication of HCV genetic material and translation into a single polypeptide, Nonstructural Protein 3 (NS3) and its activating cofactor Nonstructural Protein 4A (NS4A) are responsible for cleaving it into the following structural and nonstructural proteins required for assembly into mature virus: NS3, NS4A, NS4B, NS5A, and NS5B. By inhibiting viral protease NS3/4A, paritaprevir therefore prevents viral replication and function.
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Paritaprevir manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Paritaprevir, including repackagers and relabelers. The FDA regulates Paritaprevir manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Paritaprevir API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Paritaprevir manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Paritaprevir supplier is an individual or a company that provides Paritaprevir active pharmaceutical ingredient (API) or Paritaprevir finished formulations upon request. The Paritaprevir suppliers may include Paritaprevir API manufacturers, exporters, distributors and traders.
click here to find a list of Paritaprevir suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Paritaprevir Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Paritaprevir GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Paritaprevir GMP manufacturer or Paritaprevir GMP API supplier for your needs.
A Paritaprevir CoA (Certificate of Analysis) is a formal document that attests to Paritaprevir's compliance with Paritaprevir specifications and serves as a tool for batch-level quality control.
Paritaprevir CoA mostly includes findings from lab analyses of a specific batch. For each Paritaprevir CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Paritaprevir may be tested according to a variety of international standards, such as European Pharmacopoeia (Paritaprevir EP), Paritaprevir JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Paritaprevir USP).
LOOKING FOR A SUPPLIER?